{
    "name": "velaglucerase alfa",
    "comment": "Rx",
    "other_names": [
        "VPRIV"
    ],
    "classes": [
        "Enzymes",
        "Metabolic"
    ],
    "source": "https://reference.medscape.com/drug/vpriv-velaglucerase-alfa-999482",
    "pregnancy": {
        "common": [
            "Available data on use in pregnant females cannot definitively establish or exclude the absence of drug-associated risks during pregnancy",
            "No association was identified with use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "No fetal harm was observed in rats or rabbits when administered IV during organogenesis at doses with exposures up to 1.8 and 4.3x, respectively, the recommended human daily dose"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "Women with Type 1 Gaucher disease have an increased risk of spontaneous abortion, especially if disease symptoms are not treated and controlled preconception and during pregnancy",
                    "Pregnancy may exacerbate existing Type 1 Gaucher disease symptoms or result in new disease manifestations; these manifestations may lead to adverse pregnancy outcomes including hepatosplenomegaly and thrombocytopenia"
                ]
            }
        ]
    },
    "lactation": {
        "common": []
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [
                "The most common adverse effect are infusion-related reactions; body temperature may increase when hypersensitivity reactions occur",
                "Consider slowing infusion rate, treatment with antihistamines, antipyretics and/or corticosteroids, and/or stopping treatment if hypersensitivity reaction occurs during infusion; consider pre-treatment with antihistamines and/or corticosteroids in patients with prior reactions",
                "Most reactions are mild and occur within the first 6 months; pretreatment or symptomatic treatment with corticosteroids, antihistamines, or antipyretics may help manage the reactions",
                "Ensure that personnel administering product are adequately trained in cardiopulmonary resuscitative measures, and have ready access to emergency medical services"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": "13"
        },
        {
            "name": "Dizziness",
            "percent": "8-22"
        },
        {
            "name": "Abdominal pain",
            "percent": "15-19"
        },
        {
            "name": "Headache",
            "percent": "30-35"
        },
        {
            "name": "Upper respiratory tract infections",
            "percent": "30-32"
        },
        {
            "name": "Prolonged aPPT",
            "percent": "5-11"
        },
        {
            "name": "Flushing",
            "percent": "2"
        },
        {
            "name": "Tachycardia",
            "percent": "2"
        },
        {
            "name": "Hypertension",
            "percent": "2"
        },
        {
            "name": "hypotension",
            "percent": "2"
        },
        {
            "name": "Urticaria",
            "percent": "2"
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Chest discomfort",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        }
    ]
}